The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial

被引：54

作者：

Lazenby, M. ^{[1
,2
]}

Gilkes, A. F. ^{[1
]}

Marrin, C. ^{[1
]}

Evans, A. ^{[1
]}

Hills, R. K. ^{[1
]}

Burnett, A. K. ^{[1
,2
]}

机构：

[1] Cardiff Univ, Dept Haematol, Sch Med, Cardiff CF4 14XN, S Glam, Wales

[2] Cardiff Expt Canc Med Ctr, Cardiff, S Glam, Wales

来源：

LEUKEMIA | 2014年 / 28卷 / 10期

关键词：

ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; MICRORNA-EXPRESSION SIGNATURES; ELDERLY-PATIENTS; CHEMOTHERAPY; SURVIVAL; IMPACT; RECOMMENDATIONS; CRITERIA; OUTCOMES;

D O I：

10.1038/leu.2014.90

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although the prognostic impact of mutations of FLT3 and NPM1 have been extensively studied in younger patients with acute myeloid leukaemia, less is known in older patients whether treated intensively or non-intensively, or in the context of existing prognostic scores. In 1312 patients 16 and 21%, respectively had an FLT3 and NPM1 mutation. An FLT3 mutation did not affect remission rate in intensively or non-intensively treated patients but was associated with an inferior survival. All patients with an NPM1c mutation had a significantly higher remission rate irrespective of treatment approach but survival was not improved, overall, or in any genotype except as in younger patients, in the FLT3 WT NPM1c mutant subgroup. When incorporated into an established multi-parameter prognostic risk score, the molecular information provided additional prognostic definition in 11% of patients.

引用

页码：1953 / 1959

页数：7

共 25 条

[1] Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia [J].

Baker, Sharyn D. ;

Zimmerman, Eric I. ;

Wang, Yong-Dong ;

Orwick, Shelley ;

Zatechka, Douglas S. ;

Buaboonnam, Jassada ;

Neale, Geoffrey A. ;

Olsen, Scott R. ;

Enemark, Eric J. ;

Shurtleff, Sheila ;

Rubnitz, Jeffrey E. ;

Mullighan, Charles G. ;

Inaba, Hiroto .

CLINICAL CANCER RESEARCH, 2013, 19 (20) :5758-5768

[2] Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study [J].

Becker, Heiko ;

Marcucci, Guido ;

Maharry, Kati ;

Radmacher, Michael D. ;

Mrozek, Krzysztof ;

Margeson, Dean ;

Whitman, Susan P. ;

Wu, Yue-Zhong ;

Schwind, Sebastian ;

Paschka, Peter ;

Powell, Bayard L. ;

Carter, Thomas H. ;

Kolitz, Jonathan E. ;

Wetzler, Meir ;

Carroll, Andrew J. ;

Baer, Maria R. ;

Caligiuri, Michael A. ;

Larson, Richard A. ;

Bloomfield, Clara D. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) :596-604

[3] Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial [J].

Burnett, A. K. ;

Hills, R. K. ;

Grimwade, D. ;

Jovanovic, J. V. ;

Craig, J. ;

McMullin, M. F. ;

Kell, J. ;

Wheatley, K. ;

Yin, J. A. L. ;

Hunter, A. ;

Milligan, D. ;

Russell, N. H. .

LEUKEMIA, 2013, 27 (04) :843-851

[4] The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome [J].

Burnett, A. K. ;

Hills, R. K. ;

Hunter, A. ;

Milligan, D. ;

Kell, J. ;

Wheatley, K. ;

Yin, J. ;

McMullin, M-F ;

Cahalin, P. ;

Craig, J. ;

Bowen, D. ;

Russell, N. .

LEUKEMIA, 2011, 25 (07) :1122-1127

[5] Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival [J].

Burnett, Alan K. ;

Russell, Nigel H. ;

Hunter, Ann E. ;

Milligan, Donald ;

Knapper, Steven ;

Wheatley, Keith ;

Yin, John ;

McMullin, Mary F. ;

Ali, Sahra ;

Bowen, David ;

Hills, Robert K. .

BLOOD, 2013, 122 (08) :1384-1394

[6] Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia [J].

Burnett, Alan K. ;

Russell, Nigel H. ;

Hills, Robert K. ;

Kell, Jonathan ;

Freeman, Sylvie ;

Kjeldsen, Lars ;

Hunter, Ann E. ;

Yin, John ;

Craddock, Charles F. ;

Dufva, Inge Hoegh ;

Wheatley, Keith ;

Milligan, Donald .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) :3924-3931

[7] The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML [J].

Burnett, Alan K. ;

Russell, Nigel H. ;

Culligan, Dominic ;

Cavanagh, Jamie ;

Kell, Jonathan ;

Wheatley, Keith ;

Virchis, Andra ;

Hills, Robert K. ;

Milligan, Donald .

BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (04) :519-522

[8] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[9] Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications [J].

Falini, B. ;

Bolli, N. ;

Liso, A. ;

Martelli, M. P. ;

Mannucci, R. ;

Pileri, S. ;

Nicoletti, I. .

LEUKEMIA, 2009, 23 (10) :1731-1743

[10] The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia [J].

Gale, Rosemary E. ;

Green, Claire ;

Allen, Christopher ;

Mead, Adam J. ;

Burnett, Alan K. ;

Hils, Robert K. ;

Linch, David C. .

BLOOD, 2008, 111 (05) :2776-2784

← 1 2 3 →